Inqovi (decitabine-cedazuridine)

pCPA File Number: 21608
Negotiation Status:
Under consideration for negotiation
Indication(s):
Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups
Sponsor/Manufacturer:
Taiho Pharma Canada, Inc.
CADTH Project Number:
PC0228-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable